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Condensation: Nifedipine deteriorates fetal sheep right ventricular function and reduces right 1 
ventricular cardiac output under hypoxemia at near t rm gestation. 2 
 3 
Short Title: Nifedipine and fetal cardiac function 4 
 5 
AJOG at a Glance: 6 
A. Why was the study conducted? 7 
• Nifedipine is commonly used drug in pregnancies complicated by maternal hypertensive 8 
disorders.  9 
• Despite its widespread use during pregnancy, the possible detrimental effects of nifedipine 10 
on fetal cardiac function, especially during hypoxemia, are not fully investigated. 11 
• In a chronically instrumented sheep model, we studied whether nifedipine impacts on fetal 12 
cardiac function under hypoxemia.  13 
B. What are the key findings?  14 
• Under hypoxemia, nifedipine decreased global longitudinal strain, was related to signs of 15 
diastolic dysfunction, and ultimately reduced cardic output in the fetal right ventricle. 16 
C. What does this study add to what is already known? 17 
• In hypoxemic environment, nifedipine can have detrimental effects on fetal right ventricular 18 















Structured Abstract 1 
Background: Nifedipine is widely used drug in pregnancies complicated by maternal hypertensive 2 
disorders that can be associated with placental insuff ciency and fetal hypoxemia. The evidence 3 
regarding fetal myocardial responses to nifedipine in hypoxemia is limited. 4 
Objective: We hypothesized that nifedipine would not impair fetal sheep cardiac function under 5 
hypoxemic environment. Especially, we investigated the effects of nifedipine on fetal ventricular 6 
functional parameters and cardiac output. 7 
Study Design: A total of 21 chronically instrumented fetal sheep at 122-134 gestational days (term 8 
145 days) were included in this study. Fetal cardiac function was evaluated by measuring global 9 
longitudinal strain, indices describing ventricular systolic and diastolic function, and cardiac outputs 10 
using 2D speckle tracking, and tissue and spectral pulsed-wave Doppler echocardiography. Fetal 11 
carotid artery blood pressure and blood gas values were invasively monitored. After baseline data 12 
collection, fetal hypoxemia was induced by maternal hypoxygenation. Following hypoxemia phase 13 
data collection, 9 fetuses received nifedipine infusion, and 12 fetuses received saline infusion. Data 14 
were collected 30 and 120 minutes after the infusion was started. After 120 minutes data collection, 15 
maternal and fetal oxygenation were normalized, and normoxemia phase data were collected, while 16 
infusion was continued. 17 
Results: Hypoxemia decreased fetal carotid artery mean arteri l pressure from 40 (8) mmHg to 35 18 
(8) mmHg (p <0.007), and left ventricular global longitudinal strain showed less deformation than 19 
at baseline (p=0.001). Under hypoxemia, nifedipine caused a reduction in right ventricular global 20 
longitudinal strain (p <0.05), a decrease in right ventricular isovolumic relaxation velocity and its 21 
deceleration (p<0.01) indicating diastolic dysfunction and a drop in right ventricular cardiac output 22 










When normoxemia was restored, fetal right ventricular functional parameters and cardiac output 1 
returned to baseline level. 2 
Conclusions: In hypoxemic fetus, nifedipine impaired right ventricular function and reduced its 3 
cardiac output. The detrimental effects of nifedipine on fetal right ventricular function were 4 
abolished, when normoxemia was restored. Our findings suggest that in hypoxemic environment 5 
nifedipine triggers detrimental effects on fetal right ventricular function. 6 
 7 
Keywords: ultrasound, physiology, antihypertensive medication, heart, pregnancy, blood flow, 8 
hemodynamics, hypertension 9 











Nifedipine, a dihydropyridine calcium channel blocker, is commonly used drug in pregnancies 2 
complicated by maternal hypertensive disorders. Especially in preeclampsia, placental impairment 3 
is a common finding that can hamper fetal oxygenatio  and other gas exchange. Placental transfer 4 
of nifedipine to fetal circulation is substantial because umbilical cord serum concentration of 5 
nifedipine is about 93% of corresponding maternal serum concentration 1. Studies on sheep have 6 
shown that maternally administered nifedipine does not affect fetal blood pressure. However, it can 7 
impair uterine blood flow, potentially resulting in fetal hypoxemia and acidemia. 2 In human fetuses, 8 
maternally administered nifedipine has no detectable effect on uterine or umbilical artery blood 9 
flow velocity waveforms obtained by Doppler ultrasonography 3. Furthermore, we have shown that 10 
nifedipine when given directly to fetal circulation u der hypoxemia does not alter placental 11 
hemodynamics or umbilical artery blood flow velocity waveform 4.  12 
Myocardial contractility depends on multiple factors that include the amount of contractile proteins, 13 
Ca2+, the sensitivity of the troponin-tropomyosin system to changes in Ca2+ concentration within the 14 
cell and the interaction between actin and myosin 5. Nifedipine reduces developed pressure in 15 
immature rabbit heart at substantially lower concentrations than required in the adult heart 6. The 16 
age-related differences in mechanical function to calcium antagonists suggests that contractile force 17 
in the neonatal heart is more dependent on the slow inward calcium current than in the adult heart 5. 18 
In addition, electrophysiological studies using a mouse heart have shown a higher sensitivity of 19 
ventricular L-type Ca2+ channel current to verapamil in neonatal and infant stages than in child and 20 
adult stages 7.  21 
These results suggest that myocardial responsiveness to calcium channel blockers changes with 22 
maturation and age. In addition, the evidence concerning fetal myocardial responses to calcium 23 
channel blockers in hypoxemic environment is limited. Therefore, we designed a chronically 24 










the fetus is hypoxemic. We hypothesized that nifedipine when given directly to the fetus would not 1 
have detrimental effect on fetal cardiac function during hypoxemia. Specifically, we investigated 2 
the effect of nifedipine on fetal left (LV) and right (RV) ventricular 1) global longitudinal strain, 2)3 
indices describing ventricular systolic and diastolic function, and 3) cardiac outputs.  4 
Materials and Methods 5 
In this study, we included 21 sheep of Finnish breed with time-dated pregnancies. The study 6 
protocol was approved by the National Animal Experim nt Board of Finland 7 
(ESAVI/1007/04.10.07/ 2014). The animal care and experimental procedures were conducted 8 
according to the national legislation 8,9 and the EU Directive 2010/63/EU 10.  9 
Fetal instrumentation 10 
Fetal instrumentation was performed at 117-130 gestational days (term 145 days) under general 11 
anesthesia induced with intravenous propofol (4–7 mg/kg) and maintained with isoflurane (1.5–12 
2.5%) in an oxygen-in–air mixture delivered via an endotracheal tube. For pain relief i.v. boluses of 13 
fentanyl (0.05–0.15 mg) were administered when requi d.  14 
Following a midline laparotomy and a small hysterotomy, fetal head and upper body were 15 
delivered. Polyvinyl catheters were introduced into the external jugular vein and the carotid artery 16 
placing the catheter tips in the superior vena cava and carotid artery. A 3- lead 28-gauge silver-17 
coated copper electrocardiogram wire (New England Wire Tech., Lisbon, NH, USA) was attached 18 
subcutaneously on the fetal chest.  A separate polyvinyl catheter was placed in the amniotic cavity 19 
to monitor intra-amniotic pressure. The lost amniotic fluid was replaced with warm 0.9% saline 20 
solution. All incisions were closed, and the fetus received an intra-amniotic injection of penicillin G 21 
(1 million Units). All catheters and wires were tunnelled to a pouch on the ewe’s flank. Post-22 
operative pain was controlled with oxycodone given ia an epidural catheter that was placed to the 23 










Experimental protocol 1 
After a 4–5-day recovery, experiments were performed under general anesthesia induced with a 2 
single bolus of propofol and maintained by isoflurane in an oxygen-in-air mixture. The depth of 3 
anesthesia was titrated to minimize its effect on maternal heart rate and blood pressure and allow for 4 
ultrasound examination without discomfort. A 16-gaue polyurethane catheter was inserted into the 5 
maternal femoral artery. Thereafter, the ewe was plced supine with a right lateral tilt and allowed 6 
to stabilize for 30 minutes before obtaining the baseline measurements. After baseline 7 
measurements were collected, the ewe was connected to a re-breathing circuit to induce maternal 8 
and fetal hypoxemia. Maternal FiO2 was reduced to reach the peripheral oxygen saturation level of 9 
80%. This was confirmed by maternal arterial blood gas values. Hypoxemia phase data 10 
(hypoxemia) were collected 30 minutes after the desired maternal oxygen saturation level was 11 
reached. After hypoxemia phase data collection was completed, 9 fetuses were allocated to receive 12 
nifedipine infusion at a rate of 1.0 mL/h (700 µg/mL) (5 µg/kg/min) into the superior vena cava. 13 
The nifedipine dose was based on the studies by Blea et al. 11 and Nugent et al. 12 and is 14 
approximately equivalent to maternal oral intake of 10 mg nifedipine1. In the control group, 12 15 
fetuses received saline infusion. Data were collected at 30 (hypoxemia + 30 min infusion) and 120 16 
(hypoxemia + 120 min infusion) minutes following commencement of infusion. After 17 
hypoxemia+120 min infusion phase data collection was completed, maternal oxygenation was 18 
returned to baseline level while infusion was continued. Maternal normoxemia was achieved within 19 
3 minutes. Recovery phase data collection (normoxemia + infusion) was started 30 minutes after 20 
maternal normoxemia was achieved (Figure 1). The mean infusion time was about 150 minutes in 21 
each group, and the calculated total mean dose of nifedipine was 1.75 mg. The steady state of the 22 
nifedipine concentration in the fetal circulation is achieved in 30-40 min after maternal infusion 1,11.23 
The total dose of nifedipine in this study is equivalent to oral administration of 10 mg nifedipine 24 










with an intravenous overdose (100 mg/kg) of pentobarbital sodium to the fetus and ewe. Fetal 1 
weights were determined postmortem.  2 
Monitoring protocol 3 
Maternal and fetal arterial blood pressures were continuously monitored with disposable pressure 4 
transducers (DT-XX, Ohmeda, Hatfield, UK). Fetal blood pressure values were referenced to intra-5 
amniotic pressure. Maternal heart rate was determined from the arterial pressure waveforms. Fetal 6 
electrocardiogram leads were connected to the ultrasound equipment to obtain fetal heart rate. 7 
Maternal and fetal blood gas values were corrected to 39°C and analyzed at each study point using 8 
an Abbot i-Stat 1 arterial blood gas analyzer (i-Stat, East Windsor, NJ, USA). 9 
Ultrasonographic data acquisition 10 
Doppler ultrasonography was performed at the end of each phase by a single investigator (J.R.) 11 
using a Vivid 7 Dimension ultrasound system (GE Vingmed Ultrasound, Horten, Norway) with a 12 
10 MHz-phased array transducer. The high-pass filter was set at minimum, and the angle of 13 
insonation was kept below 15 degrees. Ultrasonographic images were analysed offline by a single 14 
observer (L.A.) blinded to allocation of animals to nifedipine or control groups.  15 
Cine-loop images of four-chamber views were obtained. Myocardial deformation (strain) was 16 
obtained by 2D speckle tracking to assess ventricular systolic function 13. Cine-loop clips of the 17 
ultrasound examination were stored digitally. Furthe  processing and measurements were performed 18 
using an image data acquisition software (EchoPAC, GE Medical Systems, Chicago, United States). 19 
Myocardial global longitudinal strain was measured for the LV and RV in a four-chamber view. An 20 
automated tracking algorithm outlined the myocardium n consecutive frames in the cardiac cycle. 21 
If needed the manual adjustment of the region of interest was performed. The mean value of the two 22 










Tissue Doppler technique was applied to measure LV and RV lateral wall movements at the 1 
atrioventricular valve level during the cardiac cycle. The sample volume (1–1.5 mm) was placed at 2 
the level of the atrioventricular valve annuli and aligned as parallel as possible to the myocardial 3 
wall (<15° angle of insonation). Myocardial velocities were recorded during three to six cardiac 4 
cycles at a sweep speed of 100 mm/s. Isovolumic relaxation (IVRV) and contraction (IVCV) 5 
velocities of the LV and RV free wall were measured. Fetal cardiac diastolic function was evaluated 6 
using the deceleration of IVRV (IVRVdec). Systolic function was assessed by the acceleration of 7 
IVCV (IVCV acc).  
14,15 To calculate fetal cardiac outputs, the diameters of the aortic (AoV) and 8 
pulmonary (PV) valves were measured in frozen real-time images during systole with the leading-9 
edge to leading-edge method. The mean value of three separate valve diameter measurements was 10 
used to calculate the cross-sectional area (CSA) of the valve. From the blood flow velocity 11 
waveforms of the AoV and PV, time-velocity integrals (TVI) were measured and volumetric blood 12 
flows (Q) across the AoV and PV were calculated (Q = CSA × TVI × fetal heart rate) 16. Left 13 
ventricular cardiac output (LVCO) equals the AoV volumetric blood flow and right ventricular 14 
cardiac output (RVCO) equals the PV volumetric blood fl w, and their sum is the combined cardiac 15 
output (CCO). Fetal cardiac outputs were weight indexed.  16 
Statistical analysis 17 
Linear Mixed Model (LMM) was used for repeatedly measured data. Phase of the experiment and 18 
infusion of nifedipine versus saline were included as fixed effects, an interaction term, and 19 
individual fetus as the random intercept. If LMM showed a significant difference between 20 
measurement points (p(time) < 0.05), then a pairwise comparison between relevant points was 21 
performed. Difference between the groups was expressed as p(group). The groups may not show 22 
similar changes with time (interaction term). Therefo , this was expressed as p(group*time). 23 









for Windows, Version 25. Armonk, NY, USA). Data are presented as mean and standard deviation 1 
(SD) unless stated otherwise. Two-tailed p value < 0.05 was considered statistically significant.  2 
Results 3 
Maternal arterial blood pressure and heart rate remained within normal physiologic range in both 4 
groups during the experiment. Reduction in maternal pO2 during hypoxemia phases was 5 
comparable between the groups (data not shown). Mean fet l weight was 2.44 (2.00- 2.99) kg and 6 
2.51 (2.06 -2.80) kg (p=0.51) in the control and nifedipine groups. The experiments were done at 7 
the mean (SD) gestational age of 128 (2) and 126 (5) days in the control and nifedipine groups 8 
(p=0.37), respectively.  9 
At baseline, LV global longitudinal strain showed more deformation (p= 0.001) than RV global 10 
longitudinal strain.  Other ultrasonographic parameters describing ventricular systolic and diastolic 11 
function or cardiac outputs did not differ between LV and RV. 12 
During hypoxemia phase, fetal pO2 decreased (p<0.001) compared to baseline (Table 1). Other fetal13 
blood gas values remained comparable to baseline level. Fetal mean arterial pressure (MAP) 14 
decreased (p <0.007) compared to baseline (Table 1). Left ventricular global longitudinal strain 15 
demonstrated less deformation (p = 0.01) than at baseline (Table 2). Fetal tissue-Doppler derived 16 
indices of LV and RV systolic and diastolic function did not change significantly during hypoxemia 17 
phase when compared to baseline. Furthermore, fetal cardiac outputs did not differ from the 18 
baseline values.  19 
In hypoxemia + 30 min infusion phase, fetal pO2 (p<0.001) and base excess (p<0.001) were lower 20 
and lactate (p<0.001) concentrations higher than at baseline (Table 1). Both LV and RV global 21 
longitudinal strains did not change significantly from the hypoxemia phase values (Table 2). In the 22 
nifedipine group, LV IVCV (p=0.02), RV IVRV (p<0.001), and its deceleration (p<0.001) were 23 









compared to the baseline with no difference between th  groups (Table 3). In both groups, LV and 1 
RV cardiac outputs did not differ from the baseline values (Table 2).  2 
In hypoxemia + 120 min infusion phase, fetal blood gas values were comparable to hypoxemia + 30 3 
min infusion phase (Table 1). In the nifedipine group, RV global longitudinal strain showed less 4 
deformation than at baseline (p=0.03) or when compared to the control group (p=0.02) (Table 2). In 5 
addition, LV IVCV (p=0.003), and RV IVRV (p<0.001) and its deceleration (p=0.001) were less 6 
than at baseline in fetuses receiving nifedipine (Table 3). Furthermore, in the nifedipine group, 7 
RVCO was lower compared to hypoxemia (p<0.05) and hypoxemia + 30 min infusion (p<0.05) 8 
phases, as well as to the control group fetuses (p<0.05) (Table 2, Figure 2). In the control group, 9 
fetal cardiac parameters remained comparable to previous phase. 10 
In normoxemia + infusion phase, fetal pO2 was lower (p<0.05) in the nifedipine group than in the 11 
control group. In the nifedipine group, fetal LV and RV global longitudinal strains, tissue Doppler 12 
derived indices of fetal cardiac function, as well as cardiac outputs returned to baseline level.  13 
Comment 14 
Principal Findings 15 
Our focus was to investigate the effect of nifedipine on fetal cardiac function during hypoxemia. 16 
We gave nifedipine to fetal circulation, to study its direct effect on fetal cardiac function rather than 17 
those that are secondary to changes in maternal cardiov scular and uteroplacental hemodynamics. 18 
Nifedipine infusion was associated with impaired fetal RV function that manifested as reduced 19 
global longitudinal strain, decreased IVRVdec suggesting diastolic dysfunction, and finally as a drop 20 
in the RV output. These alterations cannot be explained by an increase in the afterload because fetal 21 
MAP decreased during hypoxemia. After fetal hypoxemia was reversed, fetal cardiac functional 22 
parameters in the nifedipine group were comparable to baseline values suggesting that hypoxemic 23 










Results in the Context of What is Known  1 
At baseline with fetal normoxemia, LV global longitudinal strain showed more deformation than 2 
the corresponding RV strain that is in agreement with previous observations 17,18. Under hypoxemia, 3 
LV global longitudinal strain showed less deformation than during normoxemia, while hypoxemia 4 
had no effect on RV global longitudinal strain. Reduced LV global longitudinal strain during 5 
hypoxemia could be a consequence of a drop in LV preload, direct myocardial dysfunction caused 6 
by hypoxemia or a combination of the two 18. During nifedipine infusion, RV global longitudinal 7 
strain showed a reduction in deformation, while the corresponding LV global longitudinal strain 8 
was not affected. However, during normoxemia phase wh n nifedipine infusion was continued, RV 9 
global longitudinal strain returned to baseline level. Our results suggest that nifedipine can have a 10 
detrimental effect on fetal RV function, especially when the fetus is hypoxemic. Hypoxemia itself, 11 
however, did not seem to alter RV global longitudinal strain, as in the control group it remained 12 
unchanged. Ventricular longitudinal strain is affected by ventricular loading conditions. In human 13 
fetuses, RV global longitudinal strain shows less deformation with advancing gestational age 19. 14 
This is proposed to reflect increased RV afterload, i.e., fetal blood pressure that increases with 15 
advancing gestation. In the present study, fetal MAP decreased during hypoxemia, thus the effect of 16 
reduced afterload on RV global longitudinal strain should have been the opposite. Therefore, we 17 
believe that the reduction in RV global longitudinal strain was a direct effect of nifedipine itself and 18 
reflected deteriorated RV systolic function. 19 
We found that in fetuses who received nifedipine infusion, RV IVRV and its deceleration 20 
decreased. These parameters assess the movement of the ventricular lateral wall during early 21 
diastole, when the intraventricular pressure decreases from the systemic to atrial level. The IVRVdec 22 
describes the ventricular diastolic function. The myocardial relaxation is an active process requiring 23 
energy to transport Ca2+ from cytosol into the sarcoplasmic reticulum. The release of Ca2+ from the 24 










function is impaired earlier and to a greater extent han systolic function if the energy supply is 1 
limited. 2 
Under hypoxemia, fetal RVCO decreased significantly i  fetuses who received nifedipine infusion. 3 
Ventricular output depends on diastolic and systolic function, as well as ventricular loading 4 
conditions. Fetal sheep studies have shown that RVCO can increase during hypoxemia 21. In 5 
addition, it seems that fetal RV can maintain its function better than the LV during worsening 6 
hypoxemia and acidemia 22.  In sheep fetuses with increased placental vasculr resistance and acute 7 
metabolic acidosis, RV and LV global cardiac function s preserved 23. Furthermore, in human 8 
fetuses with severe placental insufficiency and signs of increased systemic venous pressure, weight-9 
indexed combined fetal cardiac output is comparable to the fetuses with uncomplicated pregnancies 10 
24. Based on these findings, we propose that reduced RV cardiac output in the nifedipine group 11 
during hypoxemia is a result of nifedipine itself. Interestingly, these detrimental effects of 12 
nifedipine on fetal RV function disappeared when fetal normoxemia was restored.  13 
Clinical and Research Implications 14 
Nifedipine is widely used in pregnancies complicated by maternal hypertensive disorders. From 15 
clinical perspective, it is important to know the possible unfavorable effects of nifedipine on the 16 
fetus, especially on fetal cardiac function. This experimental model was developed to investigate 17 
the drug effects on the hypoxemic fetus, because placental insufficiency and fetal hypoxemia are 18 
commonly seen in pregnancies complicated by maternal hypertensive disorders. The main finding 19 
that nifedipine disturbs fetal RV function and ultimately RV cardiac output is clinically important, 20 
because in fetal circulation the RV is responsible for the blood flow in the fetal lower body and 21 
placenta. Furthermore, RV is the dominant ventricle in the fetal circulation during the second half 22 
of pregnancy carrying more than 50% of fetal combined cardiac output 26. Our results suggest that 23 
hypoxemia is needed to trigger the detrimental effects of nifedipine on fetal RV, because during 24 










restored. We propose that human fetuses who suffer from hypoxemia and a significant placental 1 
insufficiency, i.e. abnormal umbilical artery blood flow pattern could be more vulnerable to the 2 
detrimental effects of nifedipine on fetal cardiac function. Previously, we found that beta-blockers 3 
can differently affect fetal RV and LV, i.e. maternal administration of pindolol decreased fetal left 4 
ventricular cardiac output and induced vasoconstriction in the pulmonary vasculature 27. The next 5 
step in experimental research would be to mimic plaental insufficiency by embolizing placental 6 
vasculature in order to increase placental vascular resistance. Then we could explore, whether 7 
nifedipine had more detrimental effect on cardiac function when hypoxemia is associated with 8 
significant placental insufficiency. In addition, we have to determine the mechanistic pathways that 9 
lead to fetal cardiac dysfunction following nifedipine administration. Finally, it is important to 10 
investigate human fetal cardiac function in order to understand whether the response to nifedipine 11 
will be similar to sheep fetuses.  12 
Strengths and limitations 13 
The main strengths of our study include that we gave the nifedipine infusion directly into the fetal 14 
circulation in relevant concentration to investigate its effects on cardiac function to avoid those 15 
alterations that could be secondary to changes in maternal hemodynamics. In addition, we used 16 
multiple different and independent ultrasonographic modalities that are validated in previous studies 17 
to examine cardiac function 28. 18 
Our study has certain limitations. Fetal surgical intervention could constitute a major stress. 19 
However, the recovery period following surgery should be long enough for full recovery of fetal 20 
cardiovascular physiology as evidenced by normal blood gas values at baseline 29. The experiments 21 
were performed under general anesthesia that could modify fetal cardiovascular responses to 22 
hypoxemia. However, the cardiovascular system of the newborn lamb can increase oxygen delivery 23 










myocardial or peripheral cardiovascular disease, the newborn lamb can coordinate neural, 1 
endocrine, and local tissue responses to increase cardiovascular performance in hypoxemia 30. 2 
Finally, validation studies in sheep fetuses have proven that invasive and Doppler 3 
echocardiographic volume blood flow calculations correlate well 28. The intraobserver variabilities 4 
of Doppler ultrasonographic parameters of fetal sheep cardiovascular hemodynamics are 5 
comparable to those found in human fetuses during the second half of pregnancy 31,32.  6 
Conclusion 7 
We conclude that under hypoxemic conditions, nifedipine impaired fetal RV function that 8 
manifested as reduced global longitudinal strain, diastolic dysfunction, and as a drop in the RV 9 
output. After recovery from hypoxemia, cardiac functional parameters in fetuses receiving 10 
nifedipine were comparable to baseline values. Thissuggests that hypoxemic environment triggers 11 
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 Baseline Hypoxemia Group Hypoxemia 







 p-group  p-time p-time*group 
pH 7.30 (0.05) 7.30 (0.04) 
Control 7.21 (0.11) 7.15 (0.12) 7.18 (0.06) 
0.87 0.001 0.95 












2.81 (0.38)  
21.08 (2.85) 
































-0.11(2.73) -1.17 (3.21) 
Control -7.00 (5.09) -10.18 (6.01) -9.00 (3.57) 
0.37 0.001 0.85 
Nifedipine -6.00 (6.06) -8.88 (5.49) -7.33 (4.76) 
Lactate 
(mmol/l) 
2.28 (1.33) 3.89 (1.73) 
Control 7.69 (3.52) 9.73 (4.01) 9.59 (4.05) 
0.84 0.001 0.72 







35 (8) Control 38 (13) 35 (9) 39 (7) 
0.53 0.018 0.35 










Table 1. Fetal arterial blood gas values and carotid artery mean arterial blood pressure. 
 
 
Values are means with SD in parentheses. P-group indicates the level of difference between the control and nifedipine groups, p-time indicates 




























p-group p-time  p-time*group 
 
FHR (bpm) 171 (31)        
 
167 (21) 









Nifedipine 156 (22) 158 (32) 159 (28) 
Global longitudinal strain (%) 
Left ventricle  -17.1(3.6)# -14.4 (2.8) 







Nifedipine -14.6 (3.0) -14.3 (4.1) -15.3 (3.1) 
Right ventricle -13.9 (3.6) -12.4 (3.1) 







Nifedipine -11.8 (3.4) -9.7 (3.1)* -11.9 (2.7) 
Diastolic function 
Left ventricle 
IVRV (cm/s) 2.63 (1.04) 2.36 (0.91) 







Nifedipine 2.03 (0.95) 1.95 (0.69) 2.70 (1.13) 
IVRVdec (cm/s²) 3.40 (2.52) 2.39 (0.85) 







Nifedipine 2.03 (0.95) 2.08 (0.77) 3.37 (0.94) 
Right ventricle 
















Nifedipine 2.59 (1.13) 2.23 (0.50) 2.97 (0.48) 
IVRVdec (cm/s²) 3.05 (2.03) 2.17 (0.84) 







Nifedipine 2.47 (1.05) 2.75 (1.04) 3.02 (1.28) 
Systolic function 
Left ventricle 
 IVCV (cm/s) 7.34 (3.67) 6.15 (3.21) 
Control 6.12 (2.26) 6.34 (3.51) 7.01 (2.63) 
0.60 0.021 0.40 
Nifedipine 5.14 (1.38) 4.47 (0.93) 7.85 (3.76) 
 IVCVacc (cm/s²) 5.40 (2.04) 4.25 (1.57) 







Nifedipine 4.55 (2.07) 3.59 (1.11) 6.41 (4.69) 
Right ventricle 
IVCV (cm/s) 5.60 (2.28) 4.77 (1.79) 
Control 4.72 (2.05) 4.03 (1.57) 5.11 (1.60) 
0.44 0.12 0.76 
Nifedipine 4.39 (1.35) 4.52 (2.58) 4.27 (1.70) 
IVCVacc (cm/s²) 5.84 (2.70) 4.57 (1.95) 























Values are means with SD in parentheses. P-group indicates the level of difference between the control and nifedipine groups, p-time indicates 
the change in measurements over time and p-time*group indicates the group x time interaction. # p<0.001 between right and left ventricles,  




Cardiac output (ml/min/kg) 
Left ventricle  246 (76) 210 (65) 







Nifedipine 212 (93) 215 (39) 236 (89) 
Right ventricle 231 (58)  242 (91) 







Nifedipine 205 (53) 168 (55)* 192 (50) 
Combined 476 (107) 455 (116) 


















Figure 1. Timeline of the experiment. 
Figure 2. Fetal right ventricular cardiac output (RVCO) in the control and nifedipine groups during the experiment. 
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